ライフサイエンスコーパス: respiratory distress syndrome

1 y pressure in patients affected by the acute respiratory distress syndrome.

2 sis-associated organ injury, including acute respiratory distress syndrome.

3 ses diffuse alveolar damage leading to acute respiratory distress syndrome.

4 s an explanation for sepsis-associated acute respiratory distress syndrome.

5 othelial activation than those without acute respiratory distress syndrome.

6 onary pressure in patients affected by acute respiratory distress syndrome.

7 toxicity to survivors' lives following acute respiratory distress syndrome.

8 ng pulmonary fibrosis, thrombosis, and acute respiratory distress syndrome.

9 nt host immune response can lead to an acute respiratory distress syndrome.

10 ay epithelium and in lungs can lead to acute respiratory distress syndrome.

11 r bronchoalveolar lavages, piglets developed respiratory distress syndrome.

12 ute hypoxemic respiratory failure, and acute respiratory distress syndrome.

13 ripheral vascular disease, sepsis, and acute respiratory distress syndrome.

14 nly in those without sepsis-associated acute respiratory distress syndrome.

15 al ventilation, presence of shock, and acute respiratory distress syndrome.

16 nts had a pulmonary and extrapulmonary acute respiratory distress syndrome.

17 ections of the morphologic patterns in acute respiratory distress syndrome.

18 may guide the ventilatory strategy in acute respiratory distress syndrome.

19 ost-effective for patients with severe acute respiratory distress syndrome.

20 rich edema formation, the hallmarks of acute respiratory distress syndrome.

21 tal mortality during the first week of acute respiratory distress syndrome.

22 ne oxygenation (ECMO) in patients with acute respiratory distress syndrome.

23 ease utilization of proning for severe acute respiratory distress syndrome.

24 atients with influenza A pneumonia and adult respiratory distress syndrome.

25 ead space compared with extrapulmonary acute respiratory distress syndrome.

26 neficial for patients with very severe acute respiratory distress syndrome.

27 s among family members of survivors of acute respiratory distress syndrome.

28 drome, and 46% of patients with severe acute respiratory distress syndrome.

29 increase in mortality in patients with acute respiratory distress syndrome.

30 Patients with moderate to severe acute respiratory distress syndrome.

31 propriate signaling has been linked to acute respiratory distress syndrome.

32 serum IgA were correlated with severe acute respiratory distress syndrome.

33 ext from radiology reports to identify acute respiratory distress syndrome.

34 ates lung injury in an animal model of acute respiratory distress syndrome.

35 e gas exchange in patients with severe acute respiratory distress syndrome.

36 ity is a risk factor for pneumonia and acute respiratory distress syndrome.

37 d healing of the "baby lung" of severe acute respiratory distress syndrome.

38 overy after critical illnesses such as acute respiratory distress syndrome.

39 ratory infection to potentially lethal acute respiratory distress syndrome.

40 ion models for patients with pediatric acute respiratory distress syndrome.

41 extrapulmonary compared with pulmonary acute respiratory distress syndrome (10 mm Hg [7-12 mm Hg] vs

42 [71%], P = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%]

43 3%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events

44 eath in the 1109 infants were established as respiratory distress syndrome (502 [45%]); sepsis, pneum

45 s present in 67% of patients with mild acute respiratory distress syndrome, 58% of patients with mode

46 severe pathological conditions such as acute respiratory distress syndrome, acute chest syndrome, and

47 Decades of clinical research in acute respiratory distress syndrome, acute respiratory failure

48 us 86.4% of patients without pediatric acute respiratory distress syndrome (adjusted relative risk, 1

49 1.7% among patients without pediatric acute respiratory distress syndrome (adjusted relative risk, 3

50 d higher in sepsis with versus without acute respiratory distress syndrome after multivariable analys

51 ve sedated and paralyzed patients with acute respiratory distress syndrome (age 64 +/- 15 yr, body ma

52 Lung-protective ventilation for acute respiratory distress syndrome aims for providing suffici

53 , and interleukin-8 than those without acute respiratory distress syndrome (all p < 0.003).

54 entions, and prevention strategies for acute respiratory distress syndrome among severely injured chi

55 one-class models in both patients with acute respiratory distress syndrome and ARFA.

56 d review complement's role in COVID-19 acute respiratory distress syndrome and coagulopathy.

57 y state ("cytokine storm") followed by acute respiratory distress syndrome and death.

58 ulation of angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis.

59 , there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esopha

60 ute respiratory syndrome coronavirus 2 acute respiratory distress syndrome and high compliance improv

61 e care among patients with and without acute respiratory distress syndrome and hospital resource util

62 xtracorporeal membrane oxygenation for acute respiratory distress syndrome and in different subgroups

63 or sepsis patients with versus without acute respiratory distress syndrome and in relation to complic

64 Clinician diagnosis of acute respiratory distress syndrome and inclusion of acute res

65 dysfunction is common in patients with adult respiratory distress syndrome and is associated with mor

66 (ANS) are the major intervention to decrease respiratory distress syndrome and mortality from prematu

67 ical interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan dysfunction

68 monstrated good discrimination between acute respiratory distress syndrome and nonacute respiratory d

69 timated associations between pediatric acute respiratory distress syndrome and outcome using generali

70 rate of barotrauma than patients with acute respiratory distress syndrome and patients without COVID

71 eptococcus coinfection, progressing to acute respiratory distress syndrome and shock.

72 na virus 2 pneumonia is linked to both acute respiratory distress syndrome and systemic hypercoagulab

73 f glycocalyx degradation in unraveling acute respiratory distress syndrome and the cardiovascular, mi

74 c therapies to avert potentially fatal acute respiratory distress syndrome and treat hyperinflammator

75 g (e.g., duration of delirium, sepsis, acute respiratory distress syndrome), and after (e.g., early s

76 yndrome, 58% of patients with moderate acute respiratory distress syndrome, and 46% of patients with

77 evated in human BAL from patients with acute respiratory distress syndrome, and its receptor was iden

78 d mortality attributable to pneumonia, acute respiratory distress syndrome, and multiorgan failure.

79 Encephalitis, acute respiratory distress syndrome, and myocarditis were the

80 asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hy

81 mechanical ventilation, development of acute respiratory distress syndrome, and receipt of vasopresso

82 talized for COVID-19, four of whom had acute respiratory distress syndrome, and six healthy controls.

83 form, the disease is characterized by acute respiratory distress syndrome, and there are no targeted

84 1.142, 95% CI 1.059-1.231, p < 0.001), acute respiratory distress syndrome (ARDS) (OR: 10.142, 95% CI

85 it is associated with inflammation and acute respiratory distress syndrome (ARDS) and may have the ap

86 enin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory fai

87 19 (COVID-19)- vs non-COVID-19-induced acute respiratory distress syndrome (ARDS) at a single US acad

88 Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-

89 anscriptional changes in patients with acute respiratory distress syndrome (ARDS) could identify cell

90 e measured MMPs in plasma collected on acute respiratory distress syndrome (ARDS) Day 1 from 235 chil

91 Acute respiratory distress syndrome (ARDS) due to coronavirus

92 tingly, its use in adults for treating acute respiratory distress syndrome (ARDS) experienced initial

93 Rationale: Two biologic phenotypes of acute respiratory distress syndrome (ARDS) have been identifie

94 lly plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus dise

95 ith urgent evaluation of patients with acute respiratory distress syndrome (ARDS) in the emergency ro

96 ratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe

97 s coronavirus 2019 (COVID-19) disease, acute respiratory distress syndrome (ARDS) is a common and oft

98 The acute respiratory distress syndrome (ARDS) is a common cause o

99 Acute respiratory distress syndrome (ARDS) is a common feature

100 Acute respiratory distress syndrome (ARDS) is a heterogeneous

101 Acute respiratory distress syndrome (ARDS) is an inflammatory

102 garding the impact of air pollution on acute respiratory distress syndrome (ARDS) is limited, and mos

103 Rationale: Acute respiratory distress syndrome (ARDS) lacks known causal

104 ) receptor 4 (CXCR4) agonists in a rat acute respiratory distress syndrome (ARDS) model utilizing the

105 on ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring ventilato

106 ng autopsy from patients who died from acute respiratory distress syndrome (ARDS) secondary to influe

107 COVID-19 can cause acute respiratory distress syndrome (ARDS) that is rapidly pro

108 VID-19 or to treat the immune storm or acute respiratory distress syndrome (ARDS) that often causes s

109 t in ~10-15% of patients progresses to acute respiratory distress syndrome (ARDS) triggered by a cyto

110 njury in severe COVID-19 compared with acute respiratory distress syndrome (ARDS) unrelated to COVID-

111 e unit (ICU) admission, mortality, and acute respiratory distress syndrome (ARDS) were 10.9%, 4.3%, a

112 icosteroids in severe COVID-19-related acute respiratory distress syndrome (ARDS) were associated wit

113 diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently

114 euromuscular blockade in patients with acute respiratory distress syndrome (ARDS) who are receiving m

115 Rationale: Two distinct phenotypes of acute respiratory distress syndrome (ARDS) with differential c

116 ompare the immunopathology of COVID-19 acute respiratory distress syndrome (ARDS) with that of non-CO

117 e respiratory infections can result in acute respiratory distress syndrome (ARDS)(1).

118 herapy is a promising intervention for acute respiratory distress syndrome (ARDS), although trials to

119 eases such as acute lung injury (ALI), acute respiratory distress syndrome (ARDS), chronic obstructiv

120 In patients with acute respiratory distress syndrome (ARDS), the National Heart

121 In the setting of severe acute respiratory distress syndrome (ARDS), the use of prone a

122 or progress toward a life-threatening acute respiratory distress syndrome (ARDS).

123 echanical ventilation in patients with acute respiratory distress syndrome (ARDS).

124 text of coronavirus disease (COVID-19) acute respiratory distress syndrome (ARDS).

125 eatures of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

126 e caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS).

127 utor to the morbidity and mortality of acute respiratory distress syndrome (ARDS).

128 EP) in critically ill patients without acute respiratory distress syndrome (ARDS).

129 rom mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS).

130 es in a critically ill population with acute respiratory distress syndrome (ARDS).

131 injury and repair is a hallmark of the acute respiratory distress syndrome (ARDS).

132 nflammation in experimental studies of acute respiratory distress syndrome (ARDS).

133 independent predictor of mortality in acute respiratory distress syndrome (ARDS).

134 injury and improve patient outcomes in acute respiratory distress syndrome (ARDS).

135 critically ill patients with COVID-19 acute respiratory distress syndrome (ARDS).

136 isk factor for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).

137 which serves as the first event in the acute respiratory distress syndrome (ARDS).

138 have been recommended in patients with acute respiratory distress syndrome (ARDS).Objectives: To dete

139 injury (ALI) and its more severe form, acute respiratory distress syndrome are life-threatening disea

140 lung injury and its more severe form, acute respiratory distress syndrome, are life-threatening resp

141 drome but also in patients at risk for acute respiratory distress syndrome (ARFA) and then assessed t

142 cision making for management of severe acute respiratory distress syndrome at centres providing venov

143 rtality was 50.0% for severe pediatric acute respiratory distress syndrome at onset, 33.3% for modera

144 not only in patients with established acute respiratory distress syndrome but also in patients at ri

145 are present not only in patients with acute respiratory distress syndrome but also in patients at ri

146 ith mobility impairment 6 months after acute respiratory distress syndrome but discharge destination

147 ing oxygenation criteria for pediatric acute respiratory distress syndrome but without bilateral infi

148 rative treatment for the patients with acute respiratory distress syndrome, but can also exacerbate l

149 g used to support patients with severe acute respiratory distress syndrome, but its cost-effectivenes

150 is the reference imaging technique for acute respiratory distress syndrome, but requires transportati

151 ng which 110 (47%) were diagnosed with acute respiratory distress syndrome by expert annotation.

152 n the model had good face validity for acute respiratory distress syndrome characteristics but differ

153 s also associated with the presence of acute respiratory distress syndrome.Conclusions: Key features

154 The underlying etiology of acute respiratory distress syndrome could deeply influence res

155 hether patients met complete pediatric acute respiratory distress syndrome criteria via chart review.

156 red children, 103 (4.2%) met pediatric acute respiratory distress syndrome criteria.

157 gh this practical approach has reduced acute respiratory distress syndrome deaths, mortality is still

158 tive end-expiratory pressure (PEEP) in acute respiratory distress syndrome depends on recruitability.

159 Acute respiratory distress syndrome development following trau

160 n previously recognized, and pediatric acute respiratory distress syndrome development is associated

161 to predict ICU outcome at 24 hours of acute respiratory distress syndrome diagnosis.

162 The 2015 definition for pediatric acute respiratory distress syndrome did not require the presen

163 ults in major complications, including acute respiratory distress syndrome, disseminated intravascula

164 astatic infection, multiorgan failure, acute respiratory distress syndrome, disseminated intravascula

165 s breathing is common in patients with acute respiratory distress syndrome during the first 48 hours

166 l life support in patients with severe acute respiratory distress syndrome during the influenza A(H1N

167 strong evidence supporting proning in acute respiratory distress syndrome, few eligible patients rec

168 common indication for tracheostomy was acute respiratory distress syndrome, followed by failure to we

169 affecting critically ill patients with acute respiratory distress syndrome following severe acute res

170 nd mortality associated with pediatric acute respiratory distress syndrome following traumatic injury

171 or identifying high-risk patients with acute respiratory distress syndrome for enrollment into random

172 In patients with acute respiratory distress syndrome from coronavirus disease 2

173 pathophysiological characteristics of acute respiratory distress syndrome from coronavirus disease 2

174 e to barotrauma rates of patients with acute respiratory distress syndrome from February 1, 2016, to

175 tive observational cohort of pediatric acute respiratory distress syndrome from the Children's Hospit

176 Our computable phenotype for acute respiratory distress syndrome had good discrimination in

177 Among patients with sepsis, those with acute respiratory distress syndrome had higher angiopoietin-2/

178 Patients with acute respiratory distress syndrome had higher prevalence of c

179 ildren with extrapulmonary sepsis with acute respiratory distress syndrome had plasma biomarkers indi

180 ality data, primarily in patients with acute respiratory distress syndrome, have made extracorporeal

181 l, physical, and social recovery after acute respiratory distress syndrome hospitalization for at lea

182 den(s) that they associated with their acute respiratory distress syndrome hospitalization.

183 atory disease, with cytokine storm and acute respiratory distress syndrome implicated in the most sev

184 ly injure the functional lung units of acute respiratory distress syndrome in a positive feedback cyc

185 poreal membrane oxygenation for severe acute respiratory distress syndrome in adults compared with st

186 2-induced cytokine storm, which drives acute respiratory distress syndrome in coronavirus disease 201

187 ory distress syndrome and inclusion of acute respiratory distress syndrome in the differential diagno

188 ergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective

189 cohort, models for intubated pediatric acute respiratory distress syndrome (including and excluding n

190 spontaneous breathing in patients with acute respiratory distress syndrome independent of acute respi

191 inical observation suggests that early acute respiratory distress syndrome induced by the severe acut

192 Classification of patients with acute respiratory distress syndrome into hyper- and hypoinflam

193 Acute respiratory distress syndrome is a clinical syndrome cha

194 Recognition is crucial because acute respiratory distress syndrome is associated with a high

195 Clinician recognition of acute respiratory distress syndrome is associated with both sy

196 In the early stage, pulmonary acute respiratory distress syndrome is characterized by a grea

197 The acute respiratory distress syndrome is common in critically il

198 Acute respiratory distress syndrome is frequently under recogn

199 Pediatric acute respiratory distress syndrome is heterogeneous, with a p

200 Survival from acute respiratory distress syndrome is improving, and outcomes

201 xic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of de

202 d sibling, low level of Hemoglobin at birth, respiratory distress syndrome, low Hemoglobin level, blo

203 setup for the first time a long-term (72 hr) respiratory distress syndrome model in spontaneously bre

204 In an acute respiratory distress syndrome model supported with ECMO,

205 cal ventilation when viewed through an acute respiratory distress syndrome model.

206 Acute respiratory distress syndrome mortality did not change o

207 ording to the intervention arms of the acute respiratory distress syndrome network and the positive e

208 Patients were ventilated with the acute respiratory distress syndrome network and, subsequently,

209 The Acute Respiratory Distress Syndrome Network dataset had limite

210 d from the low tidal volume arm of the Acute Respiratory Distress Syndrome Network tidal volume trial

211 le organ failure in 34.3% of pediatric acute respiratory distress syndrome nonsurvivors versus neurol

212 However, acute respiratory distress syndrome often goes unrecognized.

213 to admission who fulfilled criteria of acute respiratory distress syndrome on day 1 and day 2 of acut

214 Of 285 patients with acute respiratory distress syndrome on invasive mechanical ven

215 ed lung injury in patients with severe acute respiratory distress syndrome on venovenous extracorpore

216 and PaO2/FIO2 6 hours after pediatric acute respiratory distress syndrome onset.

217 elated to sepsis, respiratory failure, acute respiratory distress syndrome, or multiple organ dysfunc

218 to identify patients meeting pediatric acute respiratory distress syndrome oxygenation criteria for g

219 Children meeting pediatric acute respiratory distress syndrome oxygenation criteria with

220 5.4% of nonsurvivors without pediatric acute respiratory distress syndrome (p = 0.001).

221 PEEPPL in subjects with extrapulmonary acute respiratory distress syndrome (p = 0.006), whereas the o

222 as the opposite was true for pulmonary acute respiratory distress syndrome (p = 0.03).

223 se patients from the perspective of an acute respiratory distress syndrome paradigm to see if any spe

224 Paediatric acute respiratory distress syndrome (PARDS) is associated with

225 ly adjunctive therapy use in pediatric acute respiratory distress syndrome (PARDS).Objectives: To des

226 pathways was explored ex vivo in human acute respiratory distress syndrome patient samples, in vitro

227 e respiratory distress syndrome and nonacute respiratory distress syndrome patients (C-statistic, 0.7

228 us 30.7% of patients without pediatric acute respiratory distress syndrome patients (p < 0.001), and

229 orical control group of 39 consecutive acute respiratory distress syndrome patients admitted to the I

230 lue higher than previously reported in acute respiratory distress syndrome patients but with large va

231 < 0.001), and only 17.5% of pediatric acute respiratory distress syndrome patients discharged home w

232 ted in a cohort of intubated pediatric acute respiratory distress syndrome patients from the Children

233 Among survivors, 77.1% of pediatric acute respiratory distress syndrome patients had functional di

234 lator-induced lung injury may occur in acute respiratory distress syndrome patients on venovenous ext

235 otential of such technique in treating acute respiratory distress syndrome patients remains to be inv

236 ; 0.96-1.06) nor did the proportion of acute respiratory distress syndrome patients requiring postdis

237 e protective mechanical ventilation in acute respiratory distress syndrome patients supported with ve

238 Mortality was 34.0% among pediatric acute respiratory distress syndrome patients versus 1.7% among

239 Mortality was 20.0% among acute respiratory distress syndrome patients versus 4.3% among

240 The first 44 coronavirus disease 2019 acute respiratory distress syndrome patients were compared wit

241 spital mortality increased from 31% in acute respiratory distress syndrome patients with no acute kid

242 was to evaluate in a large database of acute respiratory distress syndrome patients, the pulmonary ve

243 syndrome patients versus 4.3% among nonacute respiratory distress syndrome patients, with an adjusted

244 y a CT scan in mechanically ventilated acute respiratory distress syndrome patients.

245 ressure due to prone positioning among acute respiratory distress syndrome patients.

246 In experimental mild-to-moderate acute respiratory distress syndrome, positive end-expiratory p

247 -expiratory pressure levels, pulmonary acute respiratory distress syndrome presented a significantly

248 d patients with influenza A(H1N1)pdm09 acute respiratory distress syndrome, prevalence of the H275Y s

249 l toxicity manifested in patients with acute respiratory distress syndrome, protective factors agains

250 a crucial role in various diseases, such as respiratory distress syndrome (RDS) in preterm infants a

251 Respiratory Distress Syndrome (RDS) is the commonest dia

252 rapeutic treatment in neonatal patients with respiratory distress syndrome (RDS).

253 l malaria [CM] = 2.42 [1.24-4.72], p = 0.01; respiratory distress syndrome [RDS] = 4.09 [1.70-9.82],

254 Although acute respiratory distress syndrome recognition and low tidal

255 1% use of tidal volume <= 6.5 mL/kg if acute respiratory distress syndrome recognized vs 15% if not r

256 Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact.

257 ents reported multiple consequences of acute respiratory distress syndrome-related financial toxicity

258 ng recruitment in patients with severe acute respiratory distress syndrome requiring extracorporeal m

259 ease syndrome that eventually leads to acute respiratory distress syndrome requiring invasive mechani

260 s develop severe disease that leads to acute respiratory distress syndrome requiring prolonged stays

261 f coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to th

262 ipal diagnoses of respiratory failure, acute respiratory distress syndrome, respiratory arrest, or se

263 Increased acute respiratory distress syndrome severity (p = 0.01) and va

264 atory distress syndrome independent of acute respiratory distress syndrome severity, the use of contr

265 In sepsis without acute respiratory distress syndrome, soluble fms-like tyrosine

266 evere oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with

267 ratory pressure setting in adults with acute respiratory distress syndrome studies.

268 the mortality of patients with severe acute respiratory distress syndrome supported with venovenous

269 Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participat

270 order symptoms among family members of acute respiratory distress syndrome survivors is high.

271 ay were all significantly longer among acute respiratory distress syndrome survivors.

272 ing development of pulmonary embolism, acute respiratory distress syndrome, systemic inflammatory res

273 Severe COVID-19 patients develop acute respiratory distress syndrome that may progress to cytok

274 Because IL-6 is a relevant cytokine in acute respiratory distress syndrome, the blockade of its recep

275 nous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative

276 In newborn piglets with respiratory distress syndrome, the nebulization of 400 m

277 d a set of selected variables early in acute respiratory distress syndrome to determine accurate prog

278 ation of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a plan

279 reported composite outcome measure in acute respiratory distress syndrome trials.

280 ve pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation).

281 iratory syndrome coronavirus 2-related acute respiratory distress syndrome using CT scan imaging desp

282 tive models for mortality in pediatric acute respiratory distress syndrome using readily available va

283 pondents reported not working prior to acute respiratory distress syndrome, using Medicaid or Medicar

284 Diagnosing acute respiratory distress syndrome was associated with lower

285 venovenous ECMO in adults with severe acute respiratory distress syndrome was associated with reduce

286 he chart for terms that indicated that acute respiratory distress syndrome was diagnosed, in the diff

287 Acute respiratory distress syndrome was recognized in 70% of p

288 entilatory management of patients with acute respiratory distress syndrome was relatively limited, wi

289 sepsis, and muscle relaxants in severe acute respiratory distress syndrome were not replicated in sub

290 lets (n = 6/group) with surfactant-deficient respiratory distress syndrome were randomized to three c

291 sponses to PEEP.Methods: Patients with acute respiratory distress syndrome were ventilated at 15 and

292 wed improved performance in diagnosing acute respiratory distress syndrome when compared to a rule-ba

293 model had a higher discrimination for acute respiratory distress syndrome when compared with the sta

294 gA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may

295 able variables from day 0 of pediatric acute respiratory distress syndrome which outperform severity

296 CoV-2 predicted the odds of developing acute respiratory distress syndrome, which increased by 62% (C

297 recruitability in patients with severe acute respiratory distress syndrome who require extracorporeal

298 ory pressure (9 cm H2O) after inducing acute respiratory distress syndrome with oleic acid.

299 rapulmonary sepsis with versus without acute respiratory distress syndrome would have plasma biomarke

300 28 per patient with moderate to severe acute respiratory distress syndrome would represent good value